Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Latest Information Update: 15 Nov 2024
Price :
$35 *
At a glance
- Drugs Busulfan (Primary) ; Cladribine (Primary) ; Fludarabine (Primary) ; Venetoclax (Primary) ; Thiotepa
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 19 Jun 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2027.
- 19 Jun 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2027.
- 28 May 2024 Planned number of patients changed from 100 to 324.